Wave Life Sciences, Inc.
WVEQ3 FY2026Period ended Sep 30, 2026
- Fiscal period
- Q3 FY2026
- Period end
- 2026-09-30
- Report due by
- 2026-10-30from the company's last four reports
- Margin metric
- Operating margin
- Status
- Scored
- Scored against
- The 10-Q for the quarter, figures as first reported
- Locks
- Locked Oct 27, 2026, 07:35 ET
Locked
Forecasts locked Oct 27, 2026, 07:35 ET, when EDGAR accepted Wave Life Sciences, Inc.'s 8-K (2.02 Results of operations), accession 0001193125-26-432690. Anything saved after that second does not count.
Reported
Actuals as first reported in the 10-Q, accession 0001193125-26-432714, scored Oct 27, 2026. Faint ticks are every counted forecast; the shaded band is the tolerance.
Revenue, reported$13.2m
Diluted EPS, reported−$0.30
Operating margin, reported−502.0%
Forecast against actual
Members with a public profile.
No public forecasts on this target.
The formula
Each metric is scored on its own. A metric that scores above 0 is a hit. League rules
score = 100 × max(0, 1 − |forecast − actual| / tolerance)
- Revenuetolerance 10% of the actual: $1.3m
- Diluted EPStolerance 20% of the actual, at least $0.05: $0.06
- Operating margintolerance 5 percentage points